Randomized controlled trials (RCT) with concrete clinical endpoints are the gold standard on the hierarchy of medical evidence. However, there are many circumstances where RCTs are not feasible to conduct, particularly for oncology and rare diseases, and ITC/ECA can be crucial to validating the value of a treatment. As well, concrete clinical endpoints in certain indications can be difficult to quantify and ultimately insufficient to truly demonstrate the impact of the treatment, leading to the need for support through patient reported outcome measures (PROM). In this webinar, we will discuss the growth in these alternate evidence methods, the receptiveness of the key HTA bodies through case studies and ultimately, what manufacturers can do to harness the power of these tools.

• • Evaluating key trends that will affect the future of pricing in the manufacturing industry. What are the emerging pricing models and strategies to look out for in 2024 and beyond?
  • Looking ahead: how are pricing experts tackling uncertainty and getting ready for worst and best cases scenarios? Has the last two-year disruption boosted resilience in pricing functions?
  • Reflecting on dos and don’ts when rising prices in a volatile climate
  • How can pricing professionals harness change and disruption to bolster the role of pricing within the organisations?
  • To what extend can dynamic pricing principles commonly used in B2C be adapted to B2B manufacturing in order to navigate uncertainty and achieve profitable outcomes?
  • Will digital transformation’s acceleration have a real, measurable, attainable impact on pricing in manufacturing? How can digital solutions help organisations to achieve pricing maturity?

   Panelists:

  -Paola Andrea Valencia, Vice President Pricing Europe, Schneider Electric

  -Robert Irwin, Senior Vice President of Business Consulting Europe, Vendavo

  -Laura Rathjen, Head of Global Pricing, Festo

   Moderator: Olivier Dallemagne, Partner, BCG

• Royal FrieslandCampina (RFC) as a cooperative is owned by its farmers and receives its farmer’s milk “no matter what”
• The milk price paid to the farmer is both the main source of income for our farmers, but also the main cost for the company FrieslandCampina
• One of the main goals of RFC is to get the most value out of its milk as possible
• This should be achieved by allocating the right amount or milk to the highest valorizing products
• Meanwhile, pricing of these different products is aimed at optimizing value by offering the right price for the right (sub)product to the right customer at the right time
• There is especially a lot of focus on timing, as the dairy sector is a very volatile sector with market prices fluctuating significantly over time

Join this webinar with members of the Kantar XTEL team for a deep dive into the results of the company’s 3rd annual RGM Study. The study investigates the top ambitions for FMCG’s in terms of investments for the future, negative and positive impacts across revenue management, trade spend plans, top major challenges in the next 12 months and more. It’s the only CPG industry study into RGM priorities and challenges, top ambitions of FMCG leaders plus actionable recommendations for successful RGM transformation. Register today.